Topics

Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases

03:58 EDT 4 Oct 2019 | Pharmaceutical Business Review

Goldfinch Bio will assume all development and commercialization responsibilities for the treatment of rare and metabolic kidney diseases worldwide. However, the agreement grants Takeda the option, prior to

The post Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases appeared first on Pharmaceutical Business review.

Original Article: Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases

NEXT ARTICLE

More From BioPortfolio on "Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases"

Quick Search

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...